Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features.

Solis LM, Behrens C, Dong W, Suraokar M, Ozburn NC, Moran CA, Corvalan AH, Biswal S, Swisher SG, Bekele BN, Minna JD, Stewart DJ, Wistuba II.

Clin Cancer Res. 2010 Jul 15;16(14):3743-53. doi: 10.1158/1078-0432.CCR-09-3352. Epub 2010 Jun 9.

2.

Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation.

Raso MG, Behrens C, Herynk MH, Liu S, Prudkin L, Ozburn NC, Woods DM, Tang X, Mehran RJ, Moran C, Lee JJ, Wistuba II.

Clin Cancer Res. 2009 Sep 1;15(17):5359-68. doi: 10.1158/1078-0432.CCR-09-0033. Epub 2009 Aug 25.

3.

Epithelial-to-mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung.

Prudkin L, Liu DD, Ozburn NC, Sun M, Behrens C, Tang X, Brown KC, Bekele BN, Moran C, Wistuba II.

Mod Pathol. 2009 May;22(5):668-78. doi: 10.1038/modpathol.2009.19. Epub 2009 Mar 6.

4.

Loss and reduction of FUS1 protein expression is a frequent phenomenon in the pathogenesis of lung cancer.

Prudkin L, Behrens C, Liu DD, Zhou X, Ozburn NC, Bekele BN, Minna JD, Moran C, Roth JA, Ji L, Wistuba II.

Clin Cancer Res. 2008 Jan 1;14(1):41-7. doi: 10.1158/1078-0432.CCR-07-1252.

5.

KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.

Massarelli E, Varella-Garcia M, Tang X, Xavier AC, Ozburn NC, Liu DD, Bekele BN, Herbst RS, Wistuba II.

Clin Cancer Res. 2007 May 15;13(10):2890-6.

Supplemental Content

Loading ...
Support Center